Compounds > 7-thiomethylspirolactone
Page last updated: 2024-09-26

7-thiomethylspirolactone

Description

7-thiomethylspirolactone: spironolactone metabolite; RN refers to (7alpha,17alpha)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162325
CHEMBL ID3544705
SCHEMBL ID18157022
MeSH IDM0134860

Synonyms (35)

Synonym
7-thiomethylspirolactone
7|a-thiomethyl spironolactone
(7r,8r,9s,10r,13s,14s,17r)-10,13-dimethyl-7-methylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione
7-a-thiomethyl spironolactone
7alpha-thiomethyl-sl
unii-0yu66jy4wl
38753-77-4
7alpha-thiomethylspironolactone
pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-(methylthio)-3-oxo-, gamma-lactone, (7alpha,17alpha)-
7alpha-thiomethylspirolactone
0yu66jy4wl ,
7a-thiomethylspironolactone
SC-26519 ,
7.alpha.-(thiomethyl)spirolactone
(7r,8r,9s,10r,13s,14s,17r)-10,13-dimethyl-7-methylsulfanyl-spiro(2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta(a)phenanthrene-17,5'-tetrahydrofuran)-2',3-dione
7-de(acetylthio)-7.alpha.-(methylthio)spironolactone
spironolactone metabolite m4
7.alpha.-thiomethylspironolactone
3-(3-oxo-7.alpha.-methylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)propionic acid .gamma.-lactone
7.alpha.-(methylthio)spironolactone
7.alpha.-(thiomethyl)spironolactone
CHEMBL3544705
(2'r,7r,8r,9s,10r,13s,14s)-10,13-dimethyl-7-(methylthio)-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'h-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2h,4'h)-dione
SCHEMBL18157022
7-alpha-thiomethyl spironolactone
(2'r,7r,8r,10r,13s,14s)-10,13-dimethyl-7-(methylthio)-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'h-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2h,4'h)-dione
AKOS032958181
Q27237364
7 alpha -thiomethyl spironolactone
17a-hydroxy-7a-(methylthio)-3-oxo-pregn-4-ene-21-carboxylic acid gamma-lactone
DTXSID80959567
10,13-dimethyl-7-(methylsulfanyl)-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-oxolane]-3,5'(2h)-dione
7| inverted exclamation mark-(thiomethyl)spironolactone
7?-thiomethyl spironolactone
PD151134

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (41.67)18.7374
1990's5 (41.67)18.2507
2000's1 (8.33)29.6817
2010's0 (0.00)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (30.77%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (69.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
canrenone[no description available]medium123steroid lactone
spironolactone[no description available]medium1333-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
aldosterone[no description available]medium1011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
betadex[no description available]medium11cyclodextrin
furosemide[no description available]medium11chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
althiazide[no description available]medium10benzothiadiazine
digoxin[no description available]medium10cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
nadp[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
Chronic Disease0medium11
Chronic Illness0medium11
Chronically Ill0medium11
Liver Diseases0medium11
Liver Dysfunction0medium11

Research Highlights

Pharmacokinetics (2)

ArticleYear
New insights into the pharmacokinetics of spironolactone.
Clinical pharmacology and therapeutics, Volume: 38, Issue: 4		1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (2)

ArticleYear
Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
International journal of clinical pharmacology and therapeutics, Volume: 36, Issue: 4		1998
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
British journal of clinical pharmacology, Volume: 44, Issue: 1		1997
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (3)

ArticleYear
Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
International journal of clinical pharmacology and therapeutics, Volume: 35, Issue: 8		1997
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
British journal of clinical pharmacology, Volume: 44, Issue: 1		1997
New insights into the pharmacokinetics of spironolactone.
Clinical pharmacology and therapeutics, Volume: 38, Issue: 4		1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]